XNYS · Diagnostics & Research
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$718.20-0.48%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
48/100
Moderate
Score components
TickerWhale View
Thermo Fisher Scientific scores 48 out of 100 overall, which we rate moderate. Technical is its strongest area and Valuation its weakest.
What helps
- Technical
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
- Risk
Quality & growth
30%30Weak
- Revenue growth 7.2%
- EPS growth 7.4%
Valuation
25%23Weak
- P/E 38.2
- EV/Sales 6.6
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
#45 by market cap in our coverage · ~125,000 employees · Listed 1972-06-01 · www.thermofisher.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#103 / 139sector rank by TickerWhale Score
TickerWhale Score 48 vs sector average 54.6 (-6.6)
Revenue growth (industry)Top 63%
Gross margin (industry)Top 71%
Return on equity (industry)Top 53%
P/E (industry)Cheaper than 57%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
93/100Strong vs universe
Ranks 93rd of 100 covered names on our technical composite — the composite itself scores 82/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
4 buy · 2 sell · 2 neutral of 8 votes
TickerWhale rates TMO's technical setup strong — 93rd percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+29.7%
- vs 50-day+8.0%
Momentum
Mixed
- RSI (14)60 · neutral
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Mixed
- ADX (14) trend strength13· weak trend
- MACD (12,26,9)buy(histogram 0.806)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 2 sell · 2 neutral.
Result — 4 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)38.2
- P/S (TTM)5.8
- P/B5.1
- EV/EBITDA—
- EV/Sales6.6
- PEG5.17
Profitability & returns
- Gross margin40.8%
- Net margin15.0%
- ROE13.3%
- Debt/Equity0.81
Growth
- Revenue growth (YoY)7.2%
- EPS growth (YoY)7.4%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $266.5B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $44.6B | $42.9B | $42.9B |
| Gross profit | $18.2B | $17.7B | $17.1B |
| Operating income | $7.7B | $7.3B | $6.9B |
| Net income | $6.7B | $6.3B | $6.0B |
| EPS (diluted) | $17.74 | $16.53 | $15.45 |
| Free cash flow | $6.3B | $7.3B | $7.0B |
| Cash | $9.9B | $4.0B | $8.1B |
| Total debt | $39.4B | $31.3B | $34.9B |
| Equity | $53.4B | $49.6B | $46.7B |
| Net debt | $29.5B | $27.3B | $26.8B |
| Debt / equity | 0.74 | 0.63 | 0.75 |
| Liabilities / assets | 0.52 | 0.49 | 0.53 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TMOCurrentThermo Fisher Scientific | 48 | 82 | 38.2 | — | 5.1 | 6.6 | $718.20 | -0.48% | +7.2% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.